Trials / Completed
CompletedNCT01428544
Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this post-marketing surveillance study is to collect and assess information retrospectively on safety and effectiveness of fondaparinux injection in patients with venous thromboembolism (VTE) whose body weight is 100 kilograms (kg) or more, or to whom fondaparinux was injected 10 mg/day. ("Arixtra" is a trademark of the GlaxoSmithKline group of companies.)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fondaparinux sodium | For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis. |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2011-09-05
- Last updated
- 2015-07-15
Source: ClinicalTrials.gov record NCT01428544. Inclusion in this directory is not an endorsement.